Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Migraine polygenic risk score associates with efficacy of migraine-specific drugs

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Candy's foundation initiativ on Cephalalgia

    Projekt: Typer af projekterProjekt

  1. Homozygosity for SCN4A Arg1142Gln causes congenital myopathy with variable disease expression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical heterogeneity and phenotype/genotype findings in 5 families with GYG1 deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Phenotypes, genotypes, and prevalence of congenital myopathies older than 5 years in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Muscle involvement in limb-girdle muscular dystrophy with GMPPB deficiency (LGMD2T)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The genetic structure of Norway

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Objective: To assess whether the polygenic risk score (PRS) for migraine is associated with acute and/or prophylactic migraine treatment response.

Methods: We interviewed 2,219 unrelated patients at the Danish Headache Center using a semistructured interview to diagnose migraine and assess acute and prophylactic drug response. All patients were genotyped. A PRS was calculated with the linkage disequilibrium pred algorithm using summary statistics from the most recent migraine genome-wide association study comprising ∼375,000 cases and controls. The PRS was scaled to a unit corresponding to a twofold increase in migraine risk, using 929 unrelated Danish controls as reference. The association of the PRS with treatment response was assessed by logistic regression, and the predictive power of the model by area under the curve using a case-control design with treatment response as outcome.

Results: A twofold increase in migraine risk associates with positive response to migraine-specific acute treatment (odds ratio [OR] = 1.25 [95% confidence interval (CI) = 1.05-1.49]). The association between migraine risk and migraine-specific acute treatment was replicated in an independent cohort consisting of 5,616 triptan users with prescription history (OR = 3.20 [95% CI = 1.26-8.14]). No association was found for acute treatment with non-migraine-specific weak analgesics and prophylactic treatment response.

Conclusions: The migraine PRS can significantly identify subgroups of patients with a higher-than-average likelihood of a positive response to triptans, which provides a first step toward genetics-based precision medicine in migraine.

OriginalsprogEngelsk
TidsskriftNeurology. Genetics
Vol/bind5
Udgave nummer6
Sider (fra-til)e368
ISSN2376-7839
DOI
StatusUdgivet - 2019

Bibliografisk note

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

ID: 58890257